The Primary Process and Key Concepts of Economic Evaluation in Healthcare
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Economic evaluations in the healthcare are used to assess economic efficiency of pharmaceuticals and medical interventions such as diagnoses and medical procedures. This study introduces the main concepts of economic evaluation across its key steps: planning, outcome and cost calculation, modeling, cost-effectiveness results, uncertainty analysis, and decision-making. When planning an economic evaluation, we determine the study population, intervention, comparators, perspectives, time horizon, discount rates, and type of economic evaluation. In healthcare economic evaluations, outcomes include changes in mortality, the survival rate, life years, and quality-adjusted life years, while costs include medical, non-medical, and productivity costs. Model-based economic evaluations, including decision tree and Markov models, are mainly used to calculate the total costs and total effects. In cost-effectiveness or cost-utility analyses, cost-effectiveness is evaluated using the incremental cost-effectiveness ratio, which is the additional cost per one additional unit of effectiveness gained by an intervention compared with a comparator. All outcomes have uncertainties owing to limited evidence, diverse methodologies, and unexplained variation. Thus, researchers should review these uncertainties and confirm their robustness. We hope to contribute to the establishment and dissemination of economic evaluation methodologies that reflect Korean clinical and research environment and ultimately improve the rationality of healthcare policies.
Abstract
Economic evaluations in the healthcare are used to assess economic efficiency of pharmaceuticals and medical interventions such as diagnoses and medical procedures. This study introduces the main concepts of economic evaluation across its key steps: planning, outcome and cost calculation, modeling, cost-effectiveness results, uncertainty analysis, and decision-making. When planning an economic evaluation, we determine the study population, intervention, comparators, perspectives, time horizon, discount rates, and type of economic evaluation. In healthcare economic evaluations, outcomes include changes in mortality, the survival rate, life years, and quality-adjusted life years, while costs include medical, non-medical, and productivity costs. Model-based economic evaluations, including decision tree and Markov models, are mainly used to calculate the total costs and total effects. In cost-effectiveness or cost-utility analyses, cost-effectiveness is evaluated using the incremental cost-effectiveness ratio, which is the additional cost per one additional unit of effectiveness gained by an intervention compared with a comparator. All outcomes have uncertainties owing to limited evidence, diverse methodologies, and unexplained variation. Thus, researchers should review these uncertainties and confirm their robustness. We hope to contribute to the establishment and dissemination of economic evaluation methodologies that reflect Korean clinical and research environment and ultimately improve the rationality of healthcare policies.
참고문헌 (29)
- Yoo SL, "Improving patient access to new drugs in South Korea : evaluation of the national drug formulary system", Int J Environ Res Public Health, 16(2), pp.288~ (2019)
- Bae EY, "Korean guidelines for pharmacoeconomic evaluations : updates in the third version", Appl Health Econ Health Policy, 20(4), pp.467~477 (2022)
- Zhao Y, "A systematic review of pharmacoeconomic guidelines", J Med Econ, 21(1), pp.85~96 (2018)
- Neumann PJ, "Cost-effectiveness in health and medicine", pp.82~86 (2017), Oxford University Press
- Gold MR, "Cost-effectiveness in health and medicine", pp.68~ (1996), Oxford University Press
- "Guidelines for economic evaluation of pharmaceuticals" (2021)[URL]
- Oliver A, "A normative perspective on discounting health outcomes", J Health Serv Res Policy, 18(3), pp.186~189 (2013)
- Paulden M, "Discounting the recommendations of the second panel on cost-effectiveness in health and medicine", Pharmacoeconomics, 35(1), pp.5~13 (2017)
- Lee J, "A study on revision and supplementation of general guidelines for conducting preliminary feasibility studies for public corporations and quasi-governmental institutions. 2nd ed", KDI Public Investment Management Center, 190~192 (2018)
- Young-Eun Kim, "A Review of the Types and Characteristics of Healthy Life Expectancy and Methodological Issues", 예방의학회지, 55(1), pp.1~9 (2022), 대한예방의학회
- Lee YK, "South Korean time trade-offvalues for EQ-5D health states : modeling with observed values for 101 health states", Value Health, 12(8), pp.1187~1193 (2009)
- A study on the estimation of the utility of EQ-5D-5L health status in adults in Korea, "Jo MW", National Evidence-based Healthcare Collaborating Agency, 63~ (2013)
- Kim SH, "The EQ-5D-5L valuation study in Korea", Qual Life Res, 25(7), pp.1845~1852 (2016)
- A study on the valuation of Korean health-related measurement tools (HINT-8) for quality of life, "Jo MW", Korea Disease Control and Prevention Agency, 91~ (2017)
- Rascati KL, "Essentials of pharmacoeconomics", pp.9~23 (2009), Lippincott Williams & Wilkins
- Yuasa A, "Use of productivity loss", gain in cost-effectiveness analyses for drugs : a systematic review, 2021, pp.39(1), 81~97
- 김윤희, "Cost Comparison between Surgical Treatments and Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer in Korea", Gut and Liver, 9(2), pp.174~180 (2015), 거트앤리버 소화기연관학회협의회
- Akobundu E, "Cost-of-illness studies : a review of current methods", Pharmacoeconomics, 24(9), pp.869~890 (2006)
- Onukwugha E, "Cost-of-illness studies : an updated review of current methods", Pharmacoeconomics, 34(1), pp.43~58 (2016)
- Park BJ, "Evidence-based healthcare", pp.270~ (2018), Park Youngsa Publishing
- Jit M, "Modelling the epidemiology of infectious diseases for decision analysis : a primer", Pharmacoeconomics, 29(5), pp.371~386 (2011)
- "NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review" (2017)[URL]
- Bullement A, "A review of recent decision-analytic models used to evaluate the economic value of cancer treatments", Appl Health Econ Health Policy, 17(6), pp.771~780 (2019)
- Park BJ, "Evidence-based healthcare", pp.207~ (2009), Korea Medicine
- A methodological study of Korean healthcare decision-making suitable for evidence-based treatment, "Ahn JH", National Evidence-based Healthcare Collaborating Agency, 125~160 (2010)
- 배은영, "비용-효과 임계값은 무엇을 반영하여야 하나?", 보건경제와 정책연구, 24(2), pp.83~106 (2018), 한국보건경제정책학회
- A joint Asian study on cost-effectiveness in health care decision making, "Ahn JH", National Evidence-based Healthcare Collaborating Agency, 17~20 (2012)
- Song HJ, "Evaluation of willingness to pay per quality-adjusted life year for a cure: a contingent valuation method using a scenario-based survey", Medicine (Baltimore), 97(38), pp.e12453~ (2018)
- Briggs AH, "Model parameter estimation and uncertainty analysis : a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6", Med Decis Making, 32(5), pp.722~732 (2012)